Tag results:

Industry & Policy News

CDC Taps Ut for National Disease Outbreak Response Network

[UT News] The Centers for Disease Control and Prevention (CDC) chose the researchers to work with public health agencies in Texas and Massachusetts, as well as with epidemiologists nationwide, through the CDC’s Center for Forecasting and Outbreak Analytics, a major new effort that grew out of the needs and lessons of the COVID-19 pandemic.

Postdoctoral Scholar Tulika Singh Receives Prestigious Hanna Gray Fellowship

[Berkeley Public Health] The Howard Hughes Medical Institute announced the selection of the 2023 Hanna Gray Fellows, a cohort of 25 early career scientists, including Dr. Tulika Singh who wants to uncover the immune pathways that remember and reactivate broadly neutralizing antibodies.

Birmingham Launches New Dental and Biomaterials Testing Service

[University of Birmingham] University of Birmingham Enterprise announced the launch of the Birmingham Dental and Biomaterials Testing Service, to provide consultancy and a comprehensive materials testing service for dental and biomaterial manufacturers.

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for Kt-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-cell Lymphoma and...

[Kymera Therapeutics, Inc.] Kymera Therapeutics, Inc. announced that the US FDA has granted Fast Track designation to KT-333 for the treatment of R/R Cutaneous T cell Lymphoma and R/R Peripheral T cell Lymphoma.

Mounjaro Approved by NICE For Treating Type 2 Diabetes

[Diabetes UK] The National Institute for Health and Care Excellence (NICE) have published draft guidance approving the use of tirzepatide (brand name Mounjaro) for treating type 2 diabetes in England and Wales.

EBGLYSS® (Lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-Severe Atopic Dermatitis

[Almirall, S.A.] Almirall S.A. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending the marketing authorization of EBGLYSS for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy.

Popular